Prostaglandin E[1] treatment in patent ductus arteriosus dependent congenital heart defects

Verfasser / Beitragende:
[G. Tálosi, M. Katona, K. Rácz, E. Kertész, B. Onozó, S. Túri]
Ort, Verlag, Jahr:
2004
Enthalten in:
Journal of Perinatal Medicine, 32/4(2004-07-09), 368-374
Format:
Artikel (online)
ID: 378938045
LEADER caa a22 4500
001 378938045
003 CHVBK
005 20180305123645.0
007 cr unu---uuuuu
008 161128e20040709xx s 000 0 eng
024 7 0 |a 10.1515/JPM.2004.069  |2 doi 
035 |a (NATIONALLICENCE)gruyter-10.1515/JPM.2004.069 
245 0 0 |a Prostaglandin E[1] treatment in patent ductus arteriosus dependent congenital heart defects  |h [Elektronische Daten]  |c [G. Tálosi, M. Katona, K. Rácz, E. Kertész, B. Onozó, S. Túri] 
520 3 |a Prostaglandin E1 (PGE1) treatment can be life saving in patients suffering from ductus dependent congenital heart defect. We analyzed the indications and side-effects of PGE1 therapy over a five-year period. The purpose of the study was also to examine whether a change in serum electrolyte levels could be detected. Forty-nine patients were treated with PGE1 during this period. PGE1 treatment was indicated by ductus dependent systemic circulation in 16 cases, ductus dependent pulmonary circulation in 17 cases, transposition of the great arteries in 13 cases and pulmonary hypertension (persistent fetal circulation) in three cases. As early side-effects of the treatment, fever occurred in 27/49 cases while apnoea was observed in 15 patients. In a one-week-old neonate with coarctation of the aorta grade III intraventricular hemorrhage developed. A mild decrease of sodium, potassium and chloride levels and a slight shift of pH levels toward metabolic alkalosis could be detected after one day and one week of PGE1 treatment. Because of these side-effects of PGE1 patients should be monitored in an intensive care unit. According to our observations electrolyte levels may exhibit a slight decrease; however, in the case of a short-term therapy extra salt supplementation is not necessary. 
540 |a Copyright (c) 2004 by Walter de Gruyter GmbH & Co. KG 
690 7 |a Human reproduction, growth & development  |2 nationallicence 
690 7 |a Gynaecology & obstetrics  |2 nationallicence 
690 7 |a Paediatric medicine  |2 nationallicence 
700 1 |a Tálosi  |D G.  |4 aut 
700 1 |a Katona  |D M.  |4 aut 
700 1 |a Rácz  |D K.  |4 aut 
700 1 |a Kertész  |D E.  |4 aut 
700 1 |a Onozó  |D B.  |4 aut 
700 1 |a Túri  |D S.  |4 aut 
773 0 |t Journal of Perinatal Medicine  |d Walter de Gruyter  |g 32/4(2004-07-09), 368-374  |x 0300-5577  |q 32:4<368  |1 2004  |2 32  |o jpme 
856 4 0 |u https://doi.org/10.1515/JPM.2004.069  |q text/html  |z Onlinezugriff via DOI 
908 |D 1  |a research article  |2 jats 
950 |B NATIONALLICENCE  |P 856  |E 40  |u https://doi.org/10.1515/JPM.2004.069  |q text/html  |z Onlinezugriff via DOI 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Tálosi  |D G.  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Katona  |D M.  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Rácz  |D K.  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Kertész  |D E.  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Onozó  |D B.  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Túri  |D S.  |4 aut 
950 |B NATIONALLICENCE  |P 773  |E 0-  |t Journal of Perinatal Medicine  |d Walter de Gruyter  |g 32/4(2004-07-09), 368-374  |x 0300-5577  |q 32:4<368  |1 2004  |2 32  |o jpme 
900 7 |b CC0  |u http://creativecommons.org/publicdomain/zero/1.0  |2 nationallicence 
898 |a BK010053  |b XK010053  |c XK010000 
949 |B NATIONALLICENCE  |F NATIONALLICENCE  |b NL-gruyter